Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Ann Mascelli

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Annual Review of Pharmacology and Toxicology|October 13, 2010
Mechanisms of monoclonal antibody-drug interactionsHonghui Zhou, Mary Ann Mascelli
Plos One|April 4, 2015
Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administrationHongsheng Xie, Jou-Ku Chung, Mary Ann Mascelli, et al.
Thrombosis Research|May 14, 2004
Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide releaseSubrata Chakrabarti, Patricia Clutton, Sonia Varghese, et al.
Seminars in Thrombosis and Hemostasis|July 30, 2004
Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromesMary Ann Mascelli, Efthymios N Deliargyris, Lakshmi V Damaraju, et al.
Journal of Drugs in Dermatology : JDD|July 22, 2010
Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functionsCarrie Brodmerkel, Yaowei Zhu, Qun Jiao, et al.
Journal of Clinical Pharmacology|March 24, 2007
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical developmentMary Ann Mascelli, Honghui Zhou, Raymond Sweet, et al.
Clinical Pharmacology in Drug Development|August 7, 2024
Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving OpioidsMatthew W Hruska, Mary Ann Mascelli, Sam Liao, et al.
American Heart Journal|January 5, 2002
Reduced inhibition by abciximab in platelets with the PlA2 polymorphismGuy L Wheeler, Gregory A Braden, Paul F Bray, et al.
Current Medical Research and Opinion|September 14, 2006
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosisLloyd H Kasper, Daniel Everitt, Thomas P Leist, et al.
Mabs|November 30, 2011
Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disordersJacqueline M Benson, David Peritt, Bernard J Scallon, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Annual Review of Pharmacology and Toxicology|October 13, 2010
Mechanisms of monoclonal antibody-drug interactionsHonghui Zhou, Mary Ann Mascelli
Plos One|April 4, 2015
Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administrationHongsheng Xie, Jou-Ku Chung, Mary Ann Mascelli, et al.
Thrombosis Research|May 14, 2004
Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide releaseSubrata Chakrabarti, Patricia Clutton, Sonia Varghese, et al.
Seminars in Thrombosis and Hemostasis|July 30, 2004
Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromesMary Ann Mascelli, Efthymios N Deliargyris, Lakshmi V Damaraju, et al.
Journal of Drugs in Dermatology : JDD|July 22, 2010
Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functionsCarrie Brodmerkel, Yaowei Zhu, Qun Jiao, et al.
Journal of Clinical Pharmacology|March 24, 2007
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical developmentMary Ann Mascelli, Honghui Zhou, Raymond Sweet, et al.
Clinical Pharmacology in Drug Development|August 7, 2024
Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving OpioidsMatthew W Hruska, Mary Ann Mascelli, Sam Liao, et al.
American Heart Journal|January 5, 2002
Reduced inhibition by abciximab in platelets with the PlA2 polymorphismGuy L Wheeler, Gregory A Braden, Paul F Bray, et al.
Current Medical Research and Opinion|September 14, 2006
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosisLloyd H Kasper, Daniel Everitt, Thomas P Leist, et al.
Mabs|November 30, 2011
Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disordersJacqueline M Benson, David Peritt, Bernard J Scallon, et al.
Pageof 3